secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001293971-24-000006
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

bluebird bio secures up to $175M loan facility from Hercules Capital; $75M funded at close
--------------------------------------------------------------------------------

- Initial $75M term loan funded; additional tranches of $25M, $25M, and $50M available subject to milestones.
- Interest rate: Prime Rate + 1.45% cash (floor 9.95%) plus 2.45% paid-in-kind; interest-only until April 2027/2028.
- Warrants issued for 5% of each tranche (initially $3.75M worth) with 7-year term, exercisable at VWAP.
- Financial covenants include Qualified Cash >= 40% of outstanding loans and product revenue test starting Q3 2024.
- Product revenue covenant tied to LYFGENIA, ZYNTEGLO, SKYSONA sales; can be waived under certain cash or market cap conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000006/0001293971-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000129397124000006/blue-20240315.htm
  HTML page:      https://secwatch.observer/filing/0001293971-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer